Halozyme Therapeutics (HALO) P/B ratio

P/B ratio today
243.6×

Halozyme Therapeutics (HALO) trades at 243.6× its book value per share at the end of fiscal 2025. At the end of fiscal 2025 (December 31, 2025) its P/B ratio was 170.8×. That is 904.4% higher than the 17.0× of fiscal 2024. Figures as of 18 Nov 2026, 10:45 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

P/B ratio today
243.6×
P/B ratio, fiscal 2025
170.8×
Change on fiscal 2024
+904.4%
Highest on record
170.8×fiscal 2025
Lowest on record
8.4×fiscal 2018
Fiscal years on record
102015–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.

Halozyme Therapeutics P/B ratio, in more detail

Today's figure is 42.6% above the fiscal 2025 year-end.

Across the 10 fiscal year-ends on record (2015–2025), the highest was 170.8× in fiscal 2025 and the lowest 8.4× in fiscal 2018. Today's P/B ratio is above every one of the 10 fiscal year-ends on record; their median is 35.0×.

History · 10 fiscal years

P/B ratio at each fiscal year-end

The last point is today's figure; the others are fiscal year-ends.

Halozyme Therapeutics P/B ratio, year by year

Halozyme Therapeutics (HALO) P/B ratio by fiscal year
Fiscal yearP/B ratioChangeYear endedShare price at year-endBook value per share
Today243.6×—$95.97—
2025170.8× 904.4% up$67.30$0.39
202417.0× 71.3% down$47.81$2.81
202359.2× 25.6% up$36.96$0.62
202247.1× 57.2% up$56.90$1.21
202130.0× 25.1% down$40.21$1.34
202040.0× 43.4% up$42.71$1.07
201927.9× 230.4% up$17.73$0.64
20188.4× 37.6% down$14.63$1.73
201713.5×—$20.26$1.50
2016——$9.88-$0.25
201551.1×—$17.33$0.34
2014——$9.65—
2013——$14.99—
2012——$6.71—
2011——$9.51—
2010——$7.92—
2009——$5.87—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

The P/B ratio is the share price divided by book value per share — shareholders' equity on the balance sheet divided by the share count — at each fiscal year-end; a year with negative equity has no P/B.

How to read it

It compares the price with the accounting value of what the company owns net of what it owes, and matters most for banks, insurers and other balance-sheet businesses.

P/B ratio at health care companies of similar size

P/B ratio of Halozyme Therapeutics and comparable companies
CompanyP/B ratio
Kymera Therapeutics KYMR6.6×
Halozyme Therapeutics HALO224.1×
Universal Health Services UHS1.5×
Repligen RGEN4.9×

Today's market value divided by shareholders' equity at the latest fiscal year-end. A company whose statements are in another currency than its shares is left out.

More on HALO

Halozyme Therapeutics, figure by figure

Halozyme Therapeutics (HALO) overview: price, valuation and scorecardAll health care companies by market value

Halozyme Therapeutics P/B ratio: questions and answers

What is Halozyme Therapeutics's P/B ratio?

Halozyme Therapeutics (HALO) trades at 243.6× its book value per share at the end of fiscal 2025. At the end of fiscal 2025 (December 31, 2025) its P/B ratio was 170.8×. That is 904.4% higher than the 17.0× of fiscal 2024.

Is Halozyme Therapeutics's P/B ratio high or low compared with its own history?

Today's P/B ratio is above every one of the 10 fiscal year-ends on record; their median is 35.0×.

What are the highest and lowest P/B ratio figures on record for Halozyme Therapeutics?

Across the 10 fiscal year-ends on record (2015–2025), the highest was 170.8× in fiscal 2025 and the lowest 8.4× in fiscal 2018.

How is Halozyme Therapeutics's P/B ratio calculated?

The P/B ratio is the share price divided by book value per share — shareholders' equity on the balance sheet divided by the share count — at each fiscal year-end; a year with negative equity has no P/B. For Halozyme Therapeutics it is on record here for 10 fiscal years, 2015 to 2025.

Share prices are Yahoo Finance's monthly closes: a fiscal year-end is paired with the close of the month it falls in, and today's quote may be delayed. Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Halozyme Therapeutics (HALO) P/B ratio”, data as of 18 November 2026. https://funkfolio.com/stock/HALO/pb-ratio

Underlying data: the company's filings with the SEC and Yahoo Finance.